Просмотр новости

Найдите то, что Вас интересует

STAT+: At BIO 2026, industry wrestled with Washington politics, and making AI work better

Дата публикации: 25-06-2026 19:19:26

Biotech executives reveal concerns over Chinese biotech, the profitability of AI, and the durability of Trump's drug price moves.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1BIO 2026: AI, federal policy impacts, and general vibes0526-06-2026
2STAT+: Embryo editing advances reignite ethical debates0526-06-2026
3Nvidia's China-bound H20 AI chips face Beijing scrutiny over ‘tracking' and security concerns0731-07-2025
4Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days0531-07-2025
5STAT+: Proposed CDC science office could tighten political control at agency-3625-06-2026
6Supreme Court rules in weedkiller cancer case0526-06-2026
7Pandemic darlings Moderna, BioNTech are now on two different paths0731-07-2025
8Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum And Strong Product-Level Performance Of GRAFAPEX (Treosulfan) For Injection5525-06-2026
9STAT+: Next-gen CRISPR tools improve editing accuracy in embryos, but also stoke ethical concerns0725-06-2026
10Деловой дайджест: 26–31 мая 2026 года0701-01-1970

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: www.statnews.com.